1. Show article details.

    Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg

    Reuters – 12:56 PM ET 07/06/2015

    - Teva Pharmaceutical Industries Ltd (TEVA) is preparing to raise its bid for rival drugmaker Mylan NV (MYL) by as much as $2 billion, to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter. The improved proposal could be announced as soon as this week, Bloomberg said.

  2. Show article details.

    Teva plans to raise Mylan bid by as much as $2 bln - Bloomberg

    Reuters – 12:53 PM ET 07/06/2015

    Teva Pharmaceutical Industries Ltd (TEVA) is preparing to raise its bid for rival drugmaker Mylan NV (MYL) by as much as $2 billion, to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter. The improved proposal could be announced as soon as this week, Bloomberg said. Teva may offer $86 to $88 per share for Mylan, up from the $82 per share it bid in April, Bloomberg reported.

  3. Show article details.

    Bemis Company Announces the Election of Ms. Adele Gulfo to Its Board of Directors

    Business Wire – 4:31 PM ET 06/29/2015

    The Board of Directors of Bemis Company, Inc. (BMS) announced today that Adele M. Gulfo was elected to the Board of Directors, effective June 23, 2015. Ms. Gulfo is Chief Strategy Officer of Mylan N.V. (MYL), a leading global pharmaceutical company, since 2014. “We are pleased that Adele is joining our Board of Directors,” said William F. Austen, Bemis Company’s President and Chief Executive Officer.

  4. Show article details.

    EU mergers and takeovers (June 25)

    Reuters – 12:25 PM ET 06/25/2015

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS. -- German car parts maker Mahle Behr to acquire U.S. car parts maker Delphi's Thermal Systems unit. -- Private equity firm Permira and investment fund Canada Pension Plan Investment Board to jointly acquire U.S. software company Informatica.

  5. Show article details.

    EU regulators to rule on Mylan bid for Perrigo by July 29

    Reuters – 12:00 PM ET 06/25/2015

    European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan should be allowed to go ahead with its $34-billion hostile bid for Perrigo (PRGO), the European Commission said. Mylan's offer is seen as a move to head off world No. 1 generic drugmaker Teva Pharmaceutical Industries (TEVA) in a high-profile takeover battle.

  6. Show article details.

    Mylan eyes Tel Aviv listing if Perrigo deal goes ahead

    Reuters – 9:07 AM ET 06/24/2015

    Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo (PRGO) for $34 billion. Sheehan was in Israel to meet Yossi Beinart, chief executive of the stock exchange.

  7. Show article details.

    Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source

    Reuters – 8:16 AM ET 06/23/2015

    Mylan NV (MYL) chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co (PRGO), an industry source said.

  8. Show article details.

    Teva raises stake in Mylan as three-way takeover battle heats up

    Reuters – 10:59 AM ET 06/19/2015

    Israel's Teva Pharmaceutical Industries Ltd (TEVA) has raised its stake in Mylan N.V. (MYL) to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.

  9. Show article details.

    Teva Takes 4.6% Stake in Mylan

    DJ Business News – 9:15 AM ET 06/19/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) said it has taken a 4.61% stake in Mylan NV (MYL), an amount that gives Teva standing in the Dutch Enterprise Chamber to commence a takeover if necessary. Teva is in the process of trying to buy Mylan, as Mylan itself has made moves to purchase Perrigo Co. Mylan executives have sharply rebuffed Teva, stating that its offer price of $82 a share in cash and stock is far too low. Perrigo (PRGO) has also fended off Mylan thus far.

  10. Show article details.

    Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

    Business Wire – 8:30 AM ET 06/19/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) today announced that it has completed the purchase of 4.61 percent of all outstanding shares of Mylan N.V. (MYL), which will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.

  11. Show article details.

    U.S. appeals court again invalidates Teva's MS drug patent

    Reuters – 12:26 PM ET 06/18/2015

    A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd (TEVA) on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.

  12. Show article details.

    U.S. Court of Appeals for the Federal Circuit Finds Teva's '808 Copaxone® Patent Invalid

    PR Newswire – 11:55 AM ET 06/18/2015

    HERTFORDSHIRE, England and PITTSBURGH, June 18, 2015Mylan N.V. (MYL) today commented on the ruling by the U.S. Court of Appeals for the Federal Circuit, which again has found Teva's U.S. Patent No. 5,800,808 for Copaxone® to be invalid as indefinite.

  13. Show article details.

    French biotechs eye U.S. for investment, markets

    Reuters – 11:30 AM ET 06/17/2015

    A group of French biotech companies working in diabetes, cancer and other fields went on the hunt this week for funding and market share in the United States, the world's biggest drugs market. About 20 biotech firms were meeting specialised North American investment funds, banks and financial analysts in New York on Wednesday and Thursday. http://bit.ly/1MIjZty.

  14. Show article details.

    Abbott Labs to Vote in Favor of Mylan's Perrigo Deal

    DJ Business News – 10:22 AM ET 06/16/2015

    Abbott Laboratories (ABT) said Tuesday that it intends to vote its 14.5% stake in Mylan NV (MYL) in favor of Mylan's proposed acquisition of rival Perrigo Co. (PRGO), a move for Mylan to help it fend off a potential takeover of its own. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, we believe Mylan's stand-alone strategy and acquisition of Perrigo (PRGO) will further enhance its platform," Abbott Chief Executive Miles White said.

  15. Show article details.

    Abbott Labs supports Mylan's bid to buy Perrigo

    MarketWatch – 9:27 AM ET 06/16/2015

    Abbott Laboratories (ABT) said on Tuesday it plans to vote its 14.5% stake in Mylan N.V. (MYL) to support Mylan's bid to buy generics company Ireland-based Perrigo Co. (PRGO). "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo (PRGO) will further enhance its platform, is strategically compelling, value enhancing for shareholders,...

  16. Show article details.

    Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction

    PR Newswire – 9:19 AM ET 06/16/2015

    HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015Mylan N.V. (MYL) today issued the following statement regarding Abbott Laboratories' (ABT) announced intention to support Mylan's offer to acquire Perrigo Company plc (PRGO) and vote in favor of this acquisition at Mylan's upcoming shareholder meeting.

  17. Show article details.

    Pulmatrix and Mylan Enter Into ex-U.S. Development Agreement for PUR0200

    PR Newswire – 7:30 AM ET 06/16/2015

    LEXINGTON, Mass. and HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V. (MYL), one of the world's leading global pharmaceutical companies.

  18. Show article details.

    India scraps import duties on AIDS drugs to battle shortage

    Reuters – 9:14 AM ET 06/11/2015

    India has scrapped customs import duties for drugs and test kits used to treat AIDS in an effort to cut prices across the country, as it struggles to cope with an ongoing shortage in its national program to fight the disease.

  19. Show article details.

    Teva switches legal counsel after Mylan challenge

    Reuters – 12:41 AM ET 06/10/2015

    Teva Pharmaceutical Industries Ltd (TEVA) has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV (MYL) after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm. Teva is now working with Sullivan & Cromwell LLP as legal counsel in its proposal to acquire Mylan, the Israeli drugmaker said late on Tuesday.

  20. Show article details.

    Judge Recommends Barring Law Firm From Advising on Teva-Mylan Takeover Fight

    DJ Business News – 9:53 PM ET 06/09/2015

    A Pennsylvania judge recommended that Kirkland& Ellis LLP be prevented from advising Teva Pharmaceutical Industries Ltd. (TEVA) on its attempted takeover of Mylan NV (MYL) after the law firm had earlier represented Mylan on other matters. Citing "the critical importance of every attorney's duty of' undivided loyalty,'" the judge held that Kirkland's earlier work for Mylan on drug approvals and other matters should bar the law firm from advising Teva, which has made a $40 billion unsolicited...

Page:

Today's and Upcoming Events

  • Aug
    6

    MYL to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.